HLA-C heavy chains free of β2-microglobulin: Distribution in normal tissues and neoplastic lesions of non-lymphoid origin and interferon-γ responsiveness

Tissue Antigens

Volumn 50, Issue 6, 1997, Pages 555-566

  Giacomini, P ^a,f   Beretta, A ^b   Nicotra, M R ^a,c   Ciccarelli, G ^a   Martayan, A ^a   Cerboni, C ^a,d   Lopalco, L ^b   Bini, D ^e   Delfino, L ^e   Ferrara, G B ^e   Siccardi, A G ^b   Natall, P G ^a  

^a CNR   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Free heavy chains; HLA C; Immunohistochemistry; Interferon ; Tissue distribution; 2 microglobin

Indexed keywords

BETA 2 MICROGLOBULIN; EPITOPE; GAMMA INTERFERON; HLA B ANTIGEN; HLA C ANTIGEN;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

MURINAE;

EID: 15144349959     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1997.tb02913.x     Document Type: Article

References (44)

1. Klein J. Tissue distribution. In: Natural history of the major histocompatibility complex. New York: John Wiley & Sons, 1986: 152-175.
2. Parham P, Barnstable CJ, Bodmer WF. Use of monoclonal antibody (W6/32) in structural studies of HLA-A,B,C antigens. J Immunol 1979: 23: 342-349.
3. McCutcheon JA, Gumperz J, Smith KD, Lutz CT, Parham P. Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA. J Exp Med 1995: 181: 2085-2095.
4. 2-microglobulin: differential effects of inhibition of glycosylation on class I subunit association. Eur J Immunol 1988: 18: 801-810.
5. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C products. J Immunol 1986: 137: 2299-2306.
6. Hajek-Rosenmayr A, Jungl L, Stammler M, Kirnbauer M. HLA-C "blank" alleles express class I gene products. Biochemical analysis of four different HLA-C "blank" polypeptides. Immunogenetics 1989: 30: 399-404.
7. Mizuno S, Kang SH, Lee HW, Trapani JA, Dupont B, Yang SY. Isolation and expression of a cDNA clone encoding HLA-Cw6: unique characteristics of HLA-C encoded gene products. Immunogenetics 1989: 29: 323-330.
8. Falk K, Rötzschke O, Grahovac B, et al. Allele specific peptide ligand motifs of HLA-C molecules. Proc Natl Acad Sci U S A 1993: 90: 12005-12009.
9. Grassi F, Meneveri R, Gullberg M, et al. Human immunodeficiency virus type 1 gp120 mimics a hidden epitope borne by class I major histocompatibility complex heavy-chains. J Exp Med 1991: 174: 53-62.
10. Setini A, Beretta A, De Santis C, et al. Distinctive features of the α1 domain α helix of HLA C heavy chains free of β2-microglobulin. Hum Immunol 1996: 46: 69-81.
11. Mandelboim O, Reyburn HT, Valés-Gómez M et al. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J Exp Med 1996: 184: 913-922.
12. Biassoni R, Falco M, Cambiaggi A et al. Amino acid substitutions can influence the natural killer (NK)-mediated recognition of HLA-C molecules. Role of serine-77 and lysine-80 in the target cell protection from lysis mediated by "group 2" or "group 1" NK clones. J Exp Med 1995: 182: 605-609.
13. Tibensky D, DeMars R, Holowachuk EW, Delovitch TL. Sequence and gene transfer analyses of HLA-CwBL18 (HLA-C blank) and HLA-Cw5 genes. J Immunol 1989: 143: 348-355.
14. Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci U S A 1993: 90: 12000-12004.
15. Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL. Specificity of HLA class I antigen recognition by human NK clones: evidence for clonal heterogeneity, protection by self and non-self alleles, and influence of the target cell type. J Exp Med 1993: 178: 1321-1336.
16. Zemmour J, Gumperz JE, Hildebrand WH et al. The molecular basis for reactivity of anti-Cw1 and anti-Cw3 alloantisera with HLA-B46 haplotypes. Tissue Antigens 1992: 39: 249-257.
17. Giacomini P, Fraioli R, Nisticò P et al. Modulation of the antigenic phenotype of early-passage human melanoma cells derived from multiple autologous metastases by recombinant human leukocyte, fibroblast and immune interferon. Int J Cancer 1990: 46: 539-545.
18. Pera C, Delfino L, Morabito A et al. HLA-A typing: comparison among serology, the amplification refractory mutation system with polymerase chain reaction and sequencing. Tissue Antigens 1997: 50: 372-379.
19. Petersdorf EW, Hansen JA. A comprehensive approach for typing the alleles of the HLA-B locus by automated sequencing. Tissue Antigens 1995: 46: 73-85.
20. Bunce M, Welsh KI. Rapid DNA typing for HLA-C using sequence-specific primers (PCR-SSP): identification of serologically and non-serologically defined HLA-C alleles including several new alleles. Tissue Antigens 1994: 43: 7-17.
21. Pellegrino MA, Ng AK, Russo C, Ferrone S. Heterogenous distribution of determinants defined by monoclonal antibodies on HLA-A, -B antigen bearing molecules. Transplantation 1982: 34: 18-23.
22. Avrameas S, Ternynck T. The cross-linking of proteins with glutaraldehyde and its use for the preparation of immunoadsorbents. Immunochemistry 1969: 6: 53-66.
23. Natali PG, Cavaliere R, Bigotti A et al. Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J Immunol 1983: 130: 1462-1466.
24. Neefjes JJ, Breur-Vriesendorp BS, Seventer I, Ivanyi P, Ploegh HL. Improved biochemical method for the analysis of HLA-class I antigens. Definition of new HLA-class I subtypes. Immunology 1986: 16: 169-181.
25. Hajek-Rosenmayr A, Jungl L, Stammler M, Kirnbauer M. HLA-C locus antigens seen by one-dimensional isoelectric focusing: definition of the so far known HLA-C specificities and of two subtypes. Hum Immunol 1989: 26: 227-236.
26. Hill A, Takiguchi M, McMichael A. Different rates of HLA class I molecule assembly which are determined by amino acid sequence in the α2 domain. Immunogenetics 1993: 37: 95-101.
27. Pollack MS, Heagney SD, Livingston PO, Fogh J. HLA-A,B,C and DR alloantigen expression on forty-six cultured human tumor cell lines. J Natl Cancer Inst 1981: 66: 1003-1011.
28. Rinaldo CR Jr. Modulation of major histocompatibility complex antigen expression by viral infection. Am J Pathol 1994: 144: 637-650.
29. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997: 18: 89-95.
30. Ljunggren H-G, Kärre K. Experimental strategies and interpretations in the analysis of changes in MHC gene expression during tumour progression: opposing influences of T cells and natural killer mediated resistance? J Immunogenet 1986: 13: 141-143.
31. Colonna M, Samaridis J. Cloning of Immunoglobulin superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995: 268: 405-408.
32. King A, Boocock C, Sharkey AM et al. Evidence for the expression of HLA-C class I mRNA and protein by human first trimester trophoblast. J Immunol 1996: 156: 2068-2076.
33. Ortiz-Navarrete V, Seelig A, Gernold M, Frentzel S, Kloetzel PM, Hämmerling GJ. Subunit of the 20S' proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex. Nature 1991: 353: 662-664.
34. Gaczynska M, Rock KL, Goldberg AL. γ-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 1993: 365: 264-267.
35. Epperson DE, Arnold D, Spies T, Cresswell P, Pober JS, Johnson DR. Cytokines increase transporter in antigen processing-1 expression more rapidly than HLA class I expression in endothelial cells. J Immunol 1992: 149: 3297-3301.
36. Bikoff EK, Jaffe L, Ribaudo RK, Otten GR, Germain RN, Robertson EJ. MHC class I surface expression in embryo-derived cell lines inducible with peptide or Interferon. Nature 1991: 354: 235-236.
37. Bikoff EK, Otten GR, Robertson EJ. Defective assembly of class I major histocompatibility complex molecules in an embryonic cell line. Eur J Immunol 1991: 21: 1997-2004.
38. 2-microglobulin by interferon-γ. EMBO J 1989: 8: 475-481.
39. Zemmour J, Parham P. Distinctive polymorphism at the HLA-C locus: implications for the expression of HLA-C. J Exp Med 1992: 176: 937-950.
40. b. Proc Natl Acad Sci U S A 1986: 83: 7447-7451.
41. d class I MHC molecules. Nature 1990: 344: 439-441.
42. Madrigal JA, Belich MP, Benjamin RJ, Little A-M, Parham P. Molecular definition of a polymorphic antigen (LA45) of free HLA-A and -B heavy chains found on the surface of activated B and T cell. J Exp Med 1991: 174: 1085-1095.
43. 2-microglobulin. J Exp Med 1990: 171: 1431-1442.
44. Matko J, Bushkin Y, Wei T, Edidin M. Clustering of class I HLA molecules on the surfaces of activated and transformed human cells. J Immunol 1994: 152: 3353-3360.